Related Experiment Video
Updated: Jun 10, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
[Effect of tongxinluo capsule on platelet aggregation function in patients with aspirin resistance]
Cheng-hua Yin1, Da-peng Bi, Min Du
1First Department of Internal Medicine, The Second People's Hospital of Jinan City. yinchenghuaey@126.com
Insights
Tongxinluo Capsule (TXLC) effectively reduces platelet aggregation in coronary heart disease (CHD) patients with aspirin resistance (AR). This herbal medicine offers a potential therapeutic option for managing AR in CHD.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Traditional Chinese Medicine
Context:
- Coronary heart disease (CHD) poses a significant global health burden.
- Aspirin resistance (AR) is a growing clinical concern in CHD management.
- Platelet aggregation plays a critical role in thrombotic events in CHD.
Purpose:
- To evaluate the efficacy of Tongxinluo Capsule (TXLC) in mitigating platelet aggregation.
- To investigate TXLC's effect in patients with coronary heart disease (CHD) who exhibit aspirin resistance (AR).
Summary:
- A study involving 330 CHD patients identified 89 (26.97%) with aspirin resistance (AR).
- Patients were randomized into three groups: TXLC + aspirin, TXLC alone, and aspirin alone, for one month.
- Both TXLC-containing groups showed significant reductions in adenosine diphosphate (ADP) and collagen (COL) induced platelet aggregation compared to aspirin alone.
Impact:
- Tongxinluo Capsule (TXLC) demonstrates a significant therapeutic effect in reducing platelet aggregation in AR patients.
- TXLC presents a promising alternative or adjunct therapy for managing aspirin resistance in coronary heart disease.
- These findings contribute to understanding novel therapeutic strategies for thrombotic risk reduction in CHD.
Objective:
To investigate the effect of Tongxinluo Capsule (TXLC) on platelet aggregation in patients of coronary heart disease (CHD) with aspirin resistance (AR).
Methods:
Patients with AR were screened out from 330 CHD patients, who had regularly taken aspirin (100 mg/d) for more than one month, by testing platelet aggregation level after adenosine diphosphate (ADP) and collagen (COL) induction. They were randomly assigned to three groups: the combined treatment group treated by TXLC + aspirin, the TXL group treated by TXLC alone and the AS group treated by aspirin alone, at the dose of TXLC 3 capsules thrice a day, and that of aspirin 100 mg/d. The therapeutic course for all was one month. Patients' platelet aggregation was measured before and after 1-month treatment.
Results:
Eighty-nine patients with AR were screened out from the 330 CHD patients, the occurrence rate being 26.97%. Platelet aggregation was significantly decreased after 1-month treatment in the combined treatment group and the TXL groups (P < 0.05), but changed insignificantly in the AS group, the difference between the former two and the latter group was statistically significant (P < 0.05).
Conclusion:
TXLC has definite effect in reducing the ADP + COL induced platelet aggregation.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins